(LOS ANGELES) — The Terasaki Institute for Biomedical Innovation (TIBI) concludes an extraordinary year of scientific discovery and technological innovation that promises to transform healthcare across multiple critical domains. Under the leadership of CEO Dr. Ali Khademhosseini, the institute has made significant strides in bioengineering, regenerative medicine, and personalized healthcare technologies.
(LOS ANGELES) — Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular filler that could transform the way diabetic wounds are treated, potentially improving patient outcomes. The groundbreaking study, published in ACS Nano, introduced an innovative approach about using specialized porous dermal fillers that accelerate tissue healing and regeneration.
(LOS ANGELES) — Researchers at the Terasaki Institute for Biomedical Innovation have developed a novel nanoparticle-based therapy for obesity treatment, as reported in a recent study published in ACS Nano. The innovative approach targets inflammatory cells in adipose tissue, modulating the immune system and promoting fat tissue browning. The research addresses the growing global obesity epidemic and the limitations of current treatment options.
(LOS ANGELES) – Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million grant from the National Institutes of Health (NIH) to advance research in organ transplantation and antibody-mediated rejection. This funding will facilitate the development of an innovative multi-organs-on-a-chip platform aimed at transforming our understanding of transplant rejection and immune tolerance.
Developing Breakthrough Contact Lens Technology for Mental Health Monitoring
(LOS ANGELES) – Yangzhi Zhu, Ph.D., Assistant Professor at the Terasaki Institute for Biomedical Innovation (TIBI), has been awarded the prestigious 2024 NARSAD Young Investigator Grant for his groundbreaking work on a lab-on-a-contact lens (LoCL) system. This innovative technology is designed to monitor mental health by providing real-time, non-invasive tracking of panels of key biomarkers, from the wearer’s tears.
(LOS ANGELES) – In a significant leap forward for healthcare equity and accessibility, researchers at the University of Victoria and the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary system that combines remote health monitoring and drug delivery using 3D-printed hollow microneedles. This innovative approach, detailed in a recent study published in Advanced Healthcare Materials, promises to transform healthcare delivery, particularly for those in underserved or remote regions.
(LOS ANGELES) - An extensive analytical study performed at the Terasaki Institute and published in Frontiers in Immunology highlights the crucial role of tissue-resident memory T cells and how they influence the immune environment of patients with non-small cell lung cancer and their overall prognosis.
(LOS ANGELES) -The team created a photocrosslinkable bioink from egg whites through methacryloyl modification. This EWMA bioink offers several advantages that make it suitable for bioprinting applications. They provide abundant proteins, ensuring a nutrient-rich environment for cell growth. These bioinks exhibit excellent biocompatibility and bioactivity, crucial for successful tissue engineering.